ENGLEWOOD, Colo., Dec. 1, 2015 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the New York Stock Exchange has established January 5, 2016 as the ex-distribution date for Ampio’s previously announced distribution to its stockholders of the shares of Common Stock of Aytu BioScience, Inc. As announced, Ampio will distribute one (1) share of Aytu common stock for every five (5) shares of Ampio Common Stock owned as of the record date, December 1, 2015. The distribution date will be January 4, 2016.
Ampio stockholders should note the following:
Ex-Distribution Date: As a result of the New York Stock Exchange establishing an ex-distribution date on January 5, 2016,
- If you sell your Ampio common stock on or prior to the distribution date, January 4, 2016, you will be selling your entitlement to the Aytu distribution.
- If you buy Ampio common stock on or prior to the distribution date, you will be entitled to the Aytu distribution so long as you still hold your Ampio stock on the ex-distribution date, January 5, 2016.
- Particularly for those stockholders who hold their Ampio stock in “street name” through their broker, the Company recommends that stockholders contact their broker to confirm they are holders of Ampio stock and that they expect one (1) Aytu share of common stock for every five (5) Ampio shares of common stock they own and request to be alerted when the Aytu shares are received in their accounts.
Ampio encourages its stockholders to consult with their financial advisors or brokers regarding the financial implications of selling Ampio stock on or prior to the distribution date.
About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Gregory A. Gould
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6513
About Aytu BioScience, Inc.
Aytu BioScience, Inc. is a commercial-stage specialty healthcare company focused on urological and related conditions. The Company’s products includes FDA-approved ProstaScint®(capromab pendetide), a radio-labeled monoclonal antibody that targets Prostate Specific Membrane Antigen (PSMA), a protein highly expressed by prostate cancer; as well as Primsol®(trimethoprim oral solution), the only FDA-approved oral solution of trimethoprim, the standard therapy for urinary tract infections. Aytu’s strategy is to continue building its portfolio of revenue-generating urology products and late-stage development assets, leveraging its commercial team and expertise to further build those brands within well-established markets.
Forward Looking Statements:
Ampio’s statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as “plan,” “continue”, “present,” “could,” “may,” “will be,” and similar expressions. These forward-looking statements include statements regarding Ampio’s plans with respect to the distribution of Aytu shares, AmpionTM and OptinaTM and their effects, which are subject to the risks associated with clinical trials, regulatory approvals, and changes in business conditions and similar events. These forward-looking statements also include statements regarding Aytu’s strategic plans and their ability to acquire potential products. These risks include the uncertainty of the regulatory response to the sufficiency of trial data and trial design, that regulatory approval may not be obtained or delayed, the risks and uncertainties detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and, the risks of timing or the ability to effect the Aytu spin-off. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.